{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:25:43Z","timestamp":1773102343952,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12325-023-02468-3","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T11:06:22Z","timestamp":1677755182000},"page":"1787-1802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct02740218","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8807-6768","authenticated-orcid":false,"given":"Petra","family":"Cetkovsk\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-3244","authenticated-orcid":false,"given":"Iva","family":"Dediol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9906-157X","authenticated-orcid":false,"given":"Marija","family":"\u0160ola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-9965","authenticated-orcid":false,"given":"Martina","family":"Kojanov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7291-8174","authenticated-orcid":false,"given":"Katarina","family":"Tr\u010dko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-1216","authenticated-orcid":false,"given":"Antoanela","family":"\u010carija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1296-6174","authenticated-orcid":false,"given":"Romana","family":"\u010ceovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-0709","authenticated-orcid":false,"given":"Daniela","family":"Ledi\u0107-Drvar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8318-8031","authenticated-orcid":false,"given":"Marija","family":"Ka\u0161telan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andina","family":"Hrabar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam Cordey","family":"Missoup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Mamun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"issue":"9997","key":"2468_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/s0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386(9997):983\u201394. https:\/\/doi.org\/10.1016\/s0140-6736(14)61909-7.","journal-title":"Lancet"},{"key":"2468_CR2","unstructured":"International Federation of Psoriasis Associations (IFPA), International League of Dermatological Societies (ILDS), International Psoriasis Council (IPC). Global Psoriasis Atlas. 2021. https:\/\/www.globalpsoriasisatlas.org\/en\/statistics\/prevalence-data."},{"issue":"2","key":"2468_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/jdv.14584","volume":"32","author":"MM Balp","year":"2018","unstructured":"Balp MM, Khalil S, Tian H, Gabriel S, Vietri J, Zuberbier T. Burden of chronic urticaria relative to psoriasis in five European countries. J Eur Acad Dermatol Venereol. 2018;32(2):282\u201390. https:\/\/doi.org\/10.1111\/jdv.14584.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"2468_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1468-3083.2008.02591.x","volume":"22","author":"B Amatya","year":"2008","unstructured":"Amatya B, Wennersten G, Nordlind K. Patients\u2019 perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol. 2008;22(7):822\u20136. https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02591.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2468_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1477-7525-7-62","volume":"7","author":"D Globe","year":"2009","unstructured":"Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes. 2009;7:62. https:\/\/doi.org\/10.1186\/1477-7525-7-62.","journal-title":"Health Qual Life Outcomes"},{"issue":"3 Pt 1","key":"2468_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/s0190-9622(99)70112-x","volume":"41","author":"SR Rapp","year":"1999","unstructured":"Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401\u20137. https:\/\/doi.org\/10.1016\/s0190-9622(99)70112-x.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2468_CR7","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871-81.e1-30. https:\/\/doi.org\/10.1016\/j.jaad.2013.12.018.","journal-title":"J Am Acad Dermatol."},{"issue":"9","key":"2468_CR8","first-page":"504","volume":"9","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Goffe B, Rice G, Mitchell M, Kaur M, Robertson D, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504\u201313.","journal-title":"Am Health Drug Benefits"},{"issue":"Suppl 2","key":"2468_CR9","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","volume":"64","author":"RG Langley","year":"2005","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18-23. https:\/\/doi.org\/10.1136\/ard.2004.033217. (discussion ii4\u20135).","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2468_CR10","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/jdv.15065","volume":"32","author":"A Armstrong","year":"2018","unstructured":"Armstrong A, Jarvis S, Boehncke WH, Rajagopalan M, Fernandez-Penas P, Romiti R, et al. Patient perceptions of clear\/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. J Eur Acad Dermatol Venereol. 2018;32(12):2200\u20137. https:\/\/doi.org\/10.1111\/jdv.15065.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2468_CR11","unstructured":"Reich K, Gisondi P, Stein Gold L, van de Kerkhof P, Langley RGP, Carle, Puig L, et al., editors. Differences in patient and dermatologist perspectives on psoriasis treatment: results from the UPLIFT survey. In: 30th European Academy of Dermatology and Venereology (EADV) congress; 2021 (virtual)."},{"issue":"1","key":"2468_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","volume":"3","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91\u2013102. https:\/\/doi.org\/10.1007\/s40744-016-0029-z.","journal-title":"Rheumatol Ther"},{"key":"2468_CR13","doi-asserted-by":"publisher","first-page":"adv00678","DOI":"10.2340\/actadv.v102.583","volume":"102","author":"N Zozaya","year":"2022","unstructured":"Zozaya N, Villoro R, Abdalla F, Alfonso Zamora S, BaleaFilgueiras J, Carrascosa Carrillo JM, et al. Unmet needs in the management of moderate-to-severe psoriasis in Spain: a multidimensional evaluation. Acta Dermato-Venereol. 2022;102:adv00678. https:\/\/doi.org\/10.2340\/actadv.v102.583.","journal-title":"Acta Dermato-Venereol."},{"issue":"2","key":"2468_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jdv.16926","volume":"35","author":"A Nast","year":"2021","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csorgo Z, Boonen H, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281\u2013317. https:\/\/doi.org\/10.1111\/jdv.16926.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"2468_CR15","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398. https:\/\/doi.org\/10.1111\/jdv.16915.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2468_CR16","doi-asserted-by":"publisher","unstructured":"Mrowietz U, Augustin M. Using the upgrade criteria of the European Psoriasis Consensus is best practice care according to the people-centred healthcare concept of the World Health Organization. Br J Dermatol. 2022;187:1007\u20138. https:\/\/doi.org\/10.1111\/bjd.21827.","DOI":"10.1111\/bjd.21827"},{"issue":"1","key":"2468_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117\u201322. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.026.","journal-title":"J Am Acad Dermatol"},{"key":"2468_CR18","unstructured":"European Medicines Agency. Otezla summary of medicinal product characteristics London: European Medicines Agency; 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_en.pdf. Accessed 04 Oct 2021."},{"issue":"1","key":"2468_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2015.03.049.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2468_CR20","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387\u201399. https:\/\/doi.org\/10.1111\/bjd.14164.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2468_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jdv.14015","volume":"31","author":"K Reich","year":"2017","unstructured":"Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507\u201317. https:\/\/doi.org\/10.1111\/jdv.14015.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"2468_CR22","first-page":"221","volume":"17","author":"L Stein Gold","year":"2018","unstructured":"Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, et al. Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL. J Drugs Dermatol. 2018;17(2):221\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"2468_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/jdv.16431","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin M, Kleyn CE, Conrad C, Sator PG, Stahle M, Eyerich K, et al. Characteristics and outcomes of patients treated with Apremilast in the real world: results from the APPRECIATE study. J Eur Acad Dermatol Venereol. 2021;35(1):123\u201334. https:\/\/doi.org\/10.1111\/jdv.16431.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2468_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13555-021-00628-3","volume":"12","author":"TM Klein","year":"2022","unstructured":"Klein TM, Blome C, Kleyn CE, Conrad C, Sator PG, Stahle M, et al. Real-world experience of patient-relevant benefits and treatment satisfaction with Apremilast in patients with psoriasis: an analysis of the APPRECIATE study. Dermatol Ther (Heidelb). 2022;12(1):81\u201395. https:\/\/doi.org\/10.1007\/s13555-021-00628-3.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2468_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2021.05.010","author":"P Herranz","year":"2021","unstructured":"Herranz P, Trasobares L, Mateu A, Mart\u00ednez E, Ruiz-Villaverde R, Baniandr\u00e9s O, et al. Characterization and outcomes in patients treated with Apremilast in routine clinical practice in Spain: results from the APPRECIATE study. Actas Dermo-Sifiliografic. 2021. https:\/\/doi.org\/10.1016\/j.ad.2021.05.010.","journal-title":"Actas Dermo-Sifiliografic"},{"issue":"2","key":"2468_CR26","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1007\/s12325-021-01981-7","volume":"39","author":"PD Ghislain","year":"2022","unstructured":"Ghislain PD, Lambert J, Hoai XL, Hillary T, Roquet-Gravy PP, de la Brassinne M, et al. Real-life effectiveness of Apremilast for the treatment of psoriasis in Belgium: results from the observational OTELO study. Adv Ther. 2022;39(2):1068\u201380. https:\/\/doi.org\/10.1007\/s12325-021-01981-7.","journal-title":"Adv Ther"},{"issue":"2","key":"2468_CR27","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s12325-021-02016-x","volume":"39","author":"K de Vlam","year":"2022","unstructured":"de Vlam K, Toukap AN, Kaiser MJ, Vanhoof J, Remans P, Van den Berghe M, et al. Real-world efficacy and safety of Apremilast in Belgian patients with psoriatic arthritis: results from the prospective observational APOLO study. Adv Ther. 2022;39(2):1055\u201367. https:\/\/doi.org\/10.1007\/s12325-021-02016-x.","journal-title":"Adv Ther"},{"issue":"9","key":"2468_CR28","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1111\/jdv.17392","volume":"35","author":"D Ioannides","year":"2021","unstructured":"Ioannides D, Antonakopoulos N, Georgiou S, Chasapi V, Katsantonis I, Drosos A, et al. Effectiveness and safety of apremilast in biologic-na\u00efve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study. J Eur Acad Dermatol Venereol. 2021;35(9):1838\u201348. https:\/\/doi.org\/10.1111\/jdv.17392.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2468_CR29","doi-asserted-by":"publisher","first-page":"204062232311527","DOI":"10.1177\/20406223231152785","volume":"14","author":"C Jonak","year":"2023","unstructured":"Jonak C, G\u00f6ttfried I, Perl-Convalexius S, Gruber B, Sch\u00fctz-Bergmayr M, Vujic I, et al. Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria\u2014results the APPRECIATE study. Ther Adv Chronic Dis. 2023;14:20406223231152784. https:\/\/doi.org\/10.1177\/20406223231152785.","journal-title":"Ther Adv Chronic Dis."},{"issue":"1","key":"2468_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.det.2014.09.005","volume":"33","author":"RJ Chalmers","year":"2015","unstructured":"Chalmers RJ. Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. Dermatol Clin. 2015;33(1):57\u201371. https:\/\/doi.org\/10.1016\/j.det.2014.09.005.","journal-title":"Dermatol Clin"},{"issue":"3","key":"2468_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"2468_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00403-012-1256-y","volume":"304","author":"J Feuerhahn","year":"2012","unstructured":"Feuerhahn J, Blome C, Radtke M, Augustin M. Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res. 2012;304(6):433\u201341. https:\/\/doi.org\/10.1007\/s00403-012-1256-y.","journal-title":"Arch Dermatol Res"},{"issue":"Suppl 1","key":"2468_CR33","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1111\/j.1524-4733.2005.00066.x","volume":"8","author":"MJ Atkinson","year":"2005","unstructured":"Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005;8(Suppl 1):S9\u201324. https:\/\/doi.org\/10.1111\/j.1524-4733.2005.00066.x.","journal-title":"Value Health"},{"issue":"3","key":"2468_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/09546634.2018.1506084","volume":"30","author":"M Amin","year":"2019","unstructured":"Amin M, Lee EB, Bhutani T, Wu JJ. Review of European registries for psoriasis. J Dermatol Treat. 2019;30(3):227\u201336. https:\/\/doi.org\/10.1080\/09546634.2018.1506084.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"2468_CR35","doi-asserted-by":"publisher","first-page":"e12589","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589. https:\/\/doi.org\/10.1111\/dth.12589.","journal-title":"Dermatol Ther."},{"issue":"4","key":"2468_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/JDN.0000000000000418","volume":"10","author":"LM Aldredge","year":"2018","unstructured":"Aldredge LM, Higham RC. Manifestations and management of difficult-to-treat psoriasis. J Dermatol Nurses\u2019 Assoc. 2018;10(4):189.","journal-title":"J Dermatol Nurses' Assoc."},{"issue":"5","key":"2468_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ced.12805","volume":"41","author":"JF Merola","year":"2016","unstructured":"Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486\u20139. https:\/\/doi.org\/10.1111\/ced.12805.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"2468_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s13555-021-00658-x","volume":"12","author":"K Reich","year":"2022","unstructured":"Reich K, Korge B, Magnolo N, Manasterski M, Schwichtenberg U, Staubach-Renz P, et al. Quality-of-life outcomes, effectiveness and tolerability of apremilast in patients with plaque psoriasis and routine German dermatology care: results from LAPIS-PSO. Dermatol Ther (Heidelb). 2022;12(1):203\u201321. https:\/\/doi.org\/10.1007\/s13555-021-00658-x.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2468_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2022.2151109","author":"I Koskivirta","year":"2023","unstructured":"Koskivirta I, Ruotsalainen J, Kurki S, Lakkakorpi P, Salminen-Mankonen H, Piril\u00e4 L, et al. Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland. Scand J Rheumatol. 2023. https:\/\/doi.org\/10.1080\/03009742.2022.2151109.","journal-title":"Scand J Rheumatol."},{"issue":"1","key":"2468_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/jpm11010020","volume":"11","author":"DA Verbenko","year":"2021","unstructured":"Verbenko DA, Karamova AE, Artamonova OG, Deryabin DG, Rakitko A, Chernitsov A, et al. Apremilast pharmacogenomics in Russian patients with moderate-to-severe and severe psoriasis. J Pers Med. 2021;11(1):20.","journal-title":"J Pers Med."},{"issue":"5","key":"2468_CR41","doi-asserted-by":"publisher","first-page":"500","DOI":"10.15690\/vramn1361","volume":"75","author":"AA Kubanov","year":"2020","unstructured":"Kubanov AA, Artamonova OG, Karamova AE, Vasileva EL, Deryabin DG. Cytokine levels of skin lesions in moderate and severe psoriasis as predictors for the type 4 fosphodiesterase inhibitor (apremilast) therapy effectivness. Ann RAMS. 2020;75(5):500\u20137. https:\/\/doi.org\/10.15690\/vramn1361.","journal-title":"Ann RAMS."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02468-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02468-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02468-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:42:02Z","timestamp":1680518522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02468-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2468"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02468-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"assertion":[{"value":"18 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}